4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $189,171.75 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 15,725 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $12.03, for a total value of $189,171.75. Following the sale, the insider owned 884,152 shares in the company, valued at approximately $10,636,348.56. The trade was a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

David Kirn also recently made the following trade(s):

• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total value of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Trading Down 7.2%

Shares of NASDAQ FDMT opened at $10.84 on Friday. The stock has a market cap of $566.72 million, a price-to-earnings ratio of -4.22 and a beta of 2.70. 4D Molecular Therapeutics, Inc. has a 52 week low of $4.14 and a 52 week high of $14.00. The company’s 50-day moving average price is $10.34 and its 200 day moving average price is $9.43.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. As a group, research analysts expect that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on FDMT shares. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Royal Bank Of Canada increased their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Jefferies Financial Group reissued a “buy” rating and set a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $29.88.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC raised its position in shares of 4D Molecular Therapeutics by 164.4% in the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after buying an additional 2,882,508 shares during the last quarter. State Street Corp boosted its position in 4D Molecular Therapeutics by 197.5% during the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after acquiring an additional 1,785,106 shares during the last quarter. RA Capital Management L.P. grew its stake in 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after acquiring an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in 4D Molecular Therapeutics by 605.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock worth $9,264,000 after acquiring an additional 1,060,156 shares during the period. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in 4D Molecular Therapeutics in the 4th quarter valued at $7,136,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.